{
    "id": 29017,
    "fullName": "TPM4 - NTRK3",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "TPM4-NTRK3 results from the fusion of TPM4 and NTRK3 (PMID: 29466156, PMID: 28719467). TPM4-NTRK3 has been associated with sarcoma (PMID: 28719467), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                },
                {
                    "id": 12997,
                    "pubMedId": 28719467,
                    "title": "Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28719467"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 7171,
        "geneSymbol": "TPM4",
        "terms": [
            "TPM4",
            "HEL-S-108"
        ]
    },
    "variant": "TPM4 - NTRK3",
    "createDate": "11/27/2018",
    "updateDate": "10/03/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4916,
                "geneSymbol": "NTRK3",
                "terms": [
                    "NTRK3",
                    "gp145(trkC)",
                    "GP145-TrkC",
                    "TRKC"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15297,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Vitrakvi (larotrectinib) treatment resulted in partial response in a patient with advanced solid tumor harboring a TPM4-NTRK3 fusion (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).",
            "molecularProfile": {
                "id": 30944,
                "profileName": "TPM4 - NTRK3"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30944,
            "profileName": "TPM4 - NTRK3",
            "profileTreatmentApproaches": [
                {
                    "id": 19354,
                    "name": "Larotrectinib",
                    "profileName": "TPM4 - NTRK3"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}